ITRM
Iterum Therapeutics PLC
NASDAQ: ITRM · HEALTHCARE · BIOTECHNOLOGY
$0.03
+0.00% today
Updated 2026-06-05
Market cap
$3.75M
P/E ratio
—
P/S ratio
9.62x
EPS (TTM)
$-0.72
Dividend yield
—
52W range
$0 – $1
Volume
188.4M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D5.0
Quality
C+2.5
Profitability
F5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$9.00
+29900.00%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-7.86M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $390000.00 |
| Net income | $-91.56M | $-44.43M | $-38.37M | $-24.77M | $-8.98M |
| EPS | — | — | — | — | $-0.72 |
| Free cash flow | $-15.90M | $-18.54M | $-39.34M | $-26.77M | $-7.86M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Iterum Therapeutics PLC trades at $0.03. Our Smart Value Score of 23/100 indicates the stock is weak. TTM revenue stands at $390000.00.
Frequently asked questions
What is Iterum Therapeutics PLC's stock price?
Iterum Therapeutics PLC (ITRM) trades at $0.03, on a P/S of 9.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Iterum Therapeutics PLC overvalued?
Iterum Therapeutics PLC carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Iterum Therapeutics PLC (ITRM)?
The 12-month analyst consensus target is $9.00, about 29900.0% above the current $0.03. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Iterum Therapeutics PLC's revenue?
Iterum Therapeutics PLC's trailing twelve-month revenue is $390000.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio9.62x
ROE-556.00%
Beta3.01
50D MA$0.26
200D MA$0.59
Shares out0.05B
Float0.05B
Short ratio—
Avg volume188.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—